“Gut-Joint Axis” Perspective on Immunometabolic Crosstalk in Osteoarthritis: A Narrative Review of Mechanistic Insights and Targeted Strategies Authors: Yufeng Zhou, Hongzhen Du, Qian Zhang, Fantao Meng, Yimeng Wang, Jilin Fan, Wei Li Published: 2026 ABSTRACT AbstractOsteoarthritis (OA) is a heterogeneous whole-joint disease in which local mechanical injury interacts with systemic metabolic dysfunction and chronic low-grade inflammation. Increasing evidence links gut microbiota dysbiosis to OA, but the mechanisms through which gut-derived perturbations contribute to joint structural damage remain incompletely integrated. This narrative review synthesizes clinical and experimental evidence on the gut–joint axis, focusing on a mechanistic sequence in which dysbiosis impairs intestinal barrier integrity, increases systemic exposure to gut-derived inflammatory signals, activates pattern-recognition receptor (PRR) signaling, and induces immunometabolic reprogramming in joint-resident cells. This process may amplify synovial inflammation, cartilage catabolism, and subchondral bone remodeling, thereby contributing to structural degeneration. Unlike previous reviews that primarily summarize microbiota-associated alterations or individual interventions, this review positions immunometabolic reprogramming as the mechanistic bridge between gut-derived inflammatory inputs and local joint degeneration. We further discuss therapeutic opportunities targeting microbiota homeostasis, intestinal barrier repair, inflammatory amplification, immunometabolic pathways, and natural products and phytochemicals. Overall, the gut–joint axis is best viewed as an amplifier of inflammatory and metabolic susceptibility rather than an independent initiator of OA. This framework may support biomarker-guided stratification and targeted interventions for metabolically driven OA. Introduction Osteoarthritis (OA) is a chronic degenerative joint disease involving cartilage, synovium, subchondral bone, and periarticular tissues. It is a leading cause of pain, mobility limitation, and functional disability among middle-aged and older adults. OA ranks among the most prevalent chronic joint disorders globally.1–3 Epidemiological data indicate that approximately 607 million people worldwide were affected by OA as of 2021.4,5 With the aging global population and increasing prevalence of obesity and metabolic disorders, the incidence of OA continues to rise, becoming a major public health concern. Pathologically, OA is characterized by progressive degeneration of articular cartilage, accompanied by remodeling of subchondral bone, synovial inflammation, and periarticular tissue abnormalities, ultimately resulting in joint pain, stiffness, and dysfunction.6–8 Traditionally, OA has been viewed as a consequence of abnormal local mechanical loading combined with age-related degeneration.1,6,7 Current treatments primarily address symptoms, including analgesia, anti-inflammatory medication, and functional improvement strategies.9,10 However, effective disease-modifying therapies capable of stably delaying or reversing joint degeneration are currently unavailable. Recent research indicates that OA is not merely a local degenerative disease; its initiation and progression are closely associated with systemic low-grade inflammation and metabolic disorders, such as obesity, insulin resistance, and dyslipidemia. Metabolic disorders provide a systemic context that amplifies local joint inflammation and structural degeneration through mechanisms including metaflammation. Thus, clarifying the relationship between systemic metabolic-immune abnormalities and local joint pathology has become a crucial research focus in OA.11–13 Importantly, OA is increasingly recognized as a heterogeneous disease involving multiple clinical and mechanistic phenotypes. In addition to mechanically driven, aging-related, and post-traumatic forms, metabolic-inflammatory OA has attracted increasing attention because of its close association with obesity, insulin resistance, dyslipidemia, and persistent systemic low-grade inflammation. Systemic metabolic-immune disturbances may lower the inflammatory activation threshold of joint tissues and amplify local responses to mechanical stress or micro-injury. Therefore, the gut–joint axis may provide a relevant framework for understanding OA pathogenesis, as gut-derived inflammatory signals and metabolic disturbances can exacerbate local inflammation and structural joint damage, particularly in metabolic-inflammatory OA phenotypes. In recent years, the concept of the gut-joint axis has provided a novel mechanistic framework linking OA with metabolic and immune abnormalities.14–16 The gut microbiota, a key microecosystem maintaining host immune homeostasis, metabolic balance, and intestinal barrier integrity, may undergo dysbiosis and barrier dysfunction. These alterations lead to changes in metabolite profiles and increased systemic exposure to gut-derived inflammatory signals, disrupting homeostasis within the joint microenvironment.17–23 Current evidence suggests these upstream gut-related changes are associated with amplified local joint inflammation and immunometabolic imbalance. However, the causal chain, key mediators, and feasibility of interventions require further integration.14,15,24–30 Recent reviews have provided important insights into gut priming in arthritis, the roles of gut and joint microbiomes in osteoarthritis, and microbiome alterations observed in patients with knee osteoarthritis.31–33 However, these reviews have primarily focused on microbiota-associated alterations, broad gut–joint interactions, or the clinical association between microbial signatures and osteoarthritis. A more integrated mechanistic framework is still needed to explain how gut-derived perturbations are translated into persistent synovitis, metabolic dysfunction in joint-resident cells, and progressive structural degeneration in osteoarthritis. Accordingly, the main novelty of the present review is to position immunometabolic reprogramming as a central mechanistic bridge between gut-derived perturbations and local joint pathology. Rather than focusing solely on changes in microbial composition, this review integrates evidence across gut dysbiosis, intestinal barrier dysfunction, microbial metabolites, systemic exposure to microbial-associated molecular patterns, pattern-recognition receptor (PRR) signaling, and metabolic reprogramming in synovial macrophages, fibroblast-like synoviocytes, and chondrocytes. In addition, this review proposes a biomarker-guided and phenotype-oriented framework for stratified intervention, with particular relevance to metabolic-inflammatory osteoarthritis. Based on these developments, this narrative review integrates clinical association studies, preclinical animal models, and cellular or mechanistic evidence to examine the gut–joint axis in OA. Its scope encompasses gut microbiota dysbiosis, intestinal barrier dysfunction, microbial metabolites and microbial-associated molecular patterns (MAMPs), PRR signaling, immunometabolic reprogramming in joint-resident cells, and potential targeted interventions. The review adopts a mechanistic, evidence-integrative approach, tracing the sequence from microbiota dysbiosis and barrier dysfunction to gut-derived inflammatory inputs, PRR activation, immunometabolic crosstalk, and subsequent joint microenvironment remodeling and structural degeneration. The aim is to provide a framework for mechanistic stratification and precision-oriented intervention in OA. An overview of this multi-layered gut–joint axis framework is presented in Figure 1. Figure 1Multi-layered framework of the gut–joint axis in osteoarthritis. This schematic summarizes the upstream gut-derived processes that may contribute to OA progression. Diet, aging, obesity, metabolic disorders, and antibiotic exposure can promote gut microbiota dysbiosis, impair intestinal barrier integrity, reduce protective microbial metabolites, and increase systemic exposure to microbial-associated molecular patterns (MAMPs). These gut-derived inputs may lower the inflammatory threshold of joint tissues and amplify local responses to mechanical stress or micro-injury, particularly in metabolic-inflammatory OA phenotypes.The diagram illustrates the gut-joint axis in osteoarthritis as a left-to-right flowchart. Upstream triggers, including a high-fat diet, obesity, antibiotic exposure, and aging, lead to gut dysbiosis, loss of protective microbial metabolites such as SCFAs, tryptophan metabolites, and bile acids, and increased intestinal permeability. These changes increase systemic exposure to gut-derived inflammatory inputs, including LPS and other MAMPs, microbial fragments, bacterial vesicles, and altered metabolite profiles, contributing to low-grade inflammation and immune priming. In the joint, PRR signaling and NLRP3 inflammasome activation promote immunometabolic crosstalk and inflammatory amplification. Feed-forward mechanisms involving the CCL2–CCR2 axis, IL-6–STAT3/Th17 bias, Treg insufficiency, complement signaling, and proposed trained immunity-like reprogramming further sustain inflammation; gut-to-joint immune cell trafficking is indicated as less established in OA. The diagram shows progression from persistent synovitis to cartilage loss, subchondral bone remodeling and osteophyte formation, and ultimately joint-space narrowing, pain, and dysfunction. The infrapatellar fat pad is shown as a local amplifier through adipokines and lipid mediators.A diagram of the gut-joint axis in osteoarthritis, showing triggers, gut dysbiosis and inflammatory signaling. Multi-layered framework of the gut–joint axis in osteoarthritis. This schematic summarizes the upstream gut-derived processes that may contribute to OA progression. Diet, aging, obesity, metabolic disorders, and antibiotic exposure can promote gut microbiota dysbiosis, impair intestinal barrier integrity, reduce protective microbial metabolites, and increase systemic exposure to microbial-associated molecular patterns (MAMPs). These gut-derived inputs may lower the inflammatory threshold of joint tissues and amplify local responses to mechanical stress or micro-injury, particularly in metabolic-inflammatory OA phenotypes. Gut Microbiota and the Gut-Joint Axis Gut Microbiota: Maintenance of Host Immune and Metabolic Homeostasis The gut microbiota is a complex community composed mainly of bacteria, alongside fungi, viruses, and archaea. Its functional gene repertoire and population size enable it to maintain host homeostasis via metabolite production, immune regulation, and interactions with the intestinal barrier. Thus, it is often considered a microecosystem with “functional organ” characteristics. The gut microbiota participates not only in local digestive functions but also significantly influences systemic immune homeostasis, metabolic regulation, and inflammatory responses.17–19,34,35 Under normal conditions, the microbiota preserves barrier integrity, restricting the translocation of microbial-associated molecular patterns (MAMPs) through co-metabolism, mucosal immune modulation, and maintaining mucus and Immunoglobulin A (IgA) layers.18,36–39 Dysbiosis, defined as deviations in microbial composition or function, often involves reduced diversity, loss of protective taxa, increased pro-inflammatory microbes, and altered metabolic outputs.16,40 Intestinal Mucosal Barrier: A Physical Defense Against Gut-Derived Pro-Inflammatory Signals The intestinal barrier consists of physical, chemical, immune, and microbial components, including epithelial cells with tight junctions, mucus layers, antimicrobial peptides, and IgA-secreting lymphoid tissues. These barriers synergistically regulate intestinal permeability and systemic exposure to MAMPs.19,21,41,42 Additionally, the gut vascular barrier (GVB) restricts entry of microbial macromolecules and particulates into systemic circulation, further controlling exposure to gut-derived inflammatory signals.43,44 As a critical upstream component of the gut-joint axis, the intestinal mucosal barrier determines whether gut microbial products and metabolites enter systemic circulation. Under normal conditions, multiple defensive layers (mucus, epithelium, tight junctions, and IgA) confine microbial products within the intestinal lumen. When barrier integrity is compromised and permeability increases, intestinal contents readily translocate into systemic circulation. This systemic exposure includes: (1) structural microbial components, including lipopolysaccharide (LPS), peptidoglycan, MAMPs, and microbial vesicles; and (2) altered metabolic profiles due to microbial dysfunction, such as decreased short-chain fatty acids (SCFAs), altered bile acids (BAs), and abnormal tryptophan metabolism.19,45 Importantly, the intestinal mucosal barrier and gut microbiota interact bidirectionally. On the one hand, the microbiota and its metabolites support barrier resilience by promoting epithelial energy metabolism, tight junction assembly, mucus layer homeostasis, and mucosal immune regulation. On the other hand, barrier integrity influences systemic exposure to microbial components and abnormal metabolites. During dysbiosis, protective signals such as SCFAs, BA metabolites, and tryptophan-derived aryl hydrocarbon receptor (AhR) ligands decrease, weakening barrier function. Consequently, bacterial components like LPS and microbial vesicles enter circulation more readily, establishing a background of low-grade inflammation.46–50 Clinically, intestinal permeability and systemic exposure to gut-derived signals are assessed indirectly using markers such as LPS, lipopolysaccharide-binding protein (LBP), soluble CD14 (sCD14), zonulin, or intestinal fatty acid-binding protein (I-FABP). However, the specificity and reproducibility of these markers are easily influenced by dietary habits, medications, and metabolic status.51–53 Thus, when considering barrier impairment as an upstream factor in OA, combined assessment using multiple markers and longitudinal studies are necessary for validation.54 Overall, compromised intestinal mucosal barrier function and its interaction with microbiota dysbiosis enhance systemic exposure to gut-derived signals, forming the upstream basis for subsequent PRR-mediated inflammatory amplification and immunometabolic crosstalk.14,19 The Gut-Joint Axis The gut-joint axis refers to a mechanistic network through which the gut microbiome remotely modulates joint tissue homeostasis and influences the occurrence and progression of OA via metabolic, immune, and neuroendocrine pathways.15,16,55 Under physiological conditions, gut microbiota maintains joint microenvironment homeostasis by preserving intestinal epithelial integrity, producing immunomodulatory metabolites, and inducing peripheral immune tolerance.16,56 However, when dietary changes, aging, obesity, or antibiotic exposure cause gut microbiota dysbiosis and intestinal mucosal barrier impairment, immunomodulatory metabolites such as SCFAs, BAs, and tryptophan derivatives decline or exhibit altered profiles, weakening receptor-mediated immunometabolic homeostasis. Barrier damage can also increase systemic exposure to MAMPs and microbial particulate carriers. In addition, changes in the intestinal mucosal immune environment could influence joint inflammation by modulating systemic immunity, although direct evidence in OA remains limited. Existing evidence suggests that, in the context of metabolic abnormalities and systemic low-grade inflammation, gut-associated immune abnormalities may enhance joint inflammatory responsiveness to mechanical stress and micro-injury, thereby lowering the inflammatory threshold of susceptible OA joints. Immunomodulatory Metabolites Gut microbiota-derived metabolites are important bioactive molecules that regulate mucosal homeostasis through specific host receptors and signaling pathways. These metabolites indirectly affect the joint microenvironment through systemic metabolic-inflammatory networks. During dysbiosis, multiple microbiota-derived immunomodulatory signals frequently decrease or change profiles, primarily characterized by reduced levels of SCFAs (particularly butyrate), altered BA profiles with weakened secondary BA and farnesoid X receptor (FXR)/G protein-coupled bile acid receptor 1 (TGR5) signaling, and imbalanced tryptophan metabolites. These alterations often coincide with functional decline.18,20,23 SCFAs Butyrate, propionate, and acetate are the main products of dietary fiber fermentation by the gut microbiota. SCFAs regulate immune homeostasis through activation of G protein-coupled receptor 41 (GPR41), G protein-coupled receptor 43 (GPR43), and histone deacetylase (HDAC)-related mechanisms.57–60 They induce regulatory T cells (Tregs) and promote anti-inflammatory cytokine production (eg, interleukin-10), thereby maintaining mucosal immune tolerance.61,62 Additionally, SCFAs support mucosal repair mediated by the group 3 innate lymphoid cell (ILC3)–interleukin-22 (IL-22) pathway, facilitating epithelial renewal and enhancing intestinal barrier function. During dysbiosis, SCFA levels often decline, weakening these homeostatic pathways. Butyrate, specifically, is a critical energy substrate for colonic epithelial cells; its reduction limits epithelial energy metabolism, compromises tight junction proteins and mucus layer stability, increases intestinal permeability, and exacerbates barrier dysfunction. Consequently, reduced SCFA levels may impair barrier support and immune tolerance, increase systemic low-grade inflammation, and lower joint inflammatory thresholds, particularly in OA phenotypes associated with obesity or metabolic disorders.45,63 In addition, altered lipid metabolite profiles during gut dysbiosis may sustain inflammation: saturated fatty acids promote pro-inflammatory activation of myeloid cells, whereas abnormal polyunsaturated fatty acid (PUFA) metabolism may disrupt inflammation resolution and homeostatic regulation.15 Tryptophan Microbiota-derived indole metabolites are crucial sources of AhR ligands, promoting IL-22 production and barrier repair.64,65 The kynurenine (Kyn) pathway influences the balance between regulatory T cells (Tregs) and T helper 17 (Th17) cells.66,67 Furthermore, tryptophan metabolism is linked to the 5-hydroxytryptamine (5-HT) pathway, potentially affecting mucosal immune homeostasis and inflammatory responses. Therefore, an imbalance in tryptophan metabolism with insufficient indole AhR ligands is associated with reduced AhR–IL-22-mediated barrier protection and disrupted Treg/Th17 balance. By analogy, similar disturbances of AhR–IL-22-mediated barrier protection in OA contexts may promote synovitis, pain sensitization, and sustained catabolic processes.68,69 BAs BAs constitute critical co-metabolic pools in microbiota-host interactions, regulating barrier and immunometabolic homeostasis through receptors such as FXR and TGR5, and shaping the microbiota and epithelial microenvironment.20,23,70–72 BA profile remodeling caused by gut dysbiosis may weaken receptor-mediated anti-inflammatory mechanisms and enhance responsiveness to MAMPs, thereby amplifying Toll-like receptor 4 (TLR4)–nuclear factor kappa-B (NF-κB) inflammatory cascades and sustaining systemic low-grade inflammation. TGR5 signaling also influences secretion of incretins such as glucagon-like peptide-1 (GLP-1), further modulating systemic inflammation and oxidative stress.73–75 In OA, impaired BA receptor-mediated regulation may increase joint susceptibility to gut-derived inflammatory inputs and metabolic disorder-associated signals, especially in metabolic-inflammatory OA phenotypes.76,77 Additionally, trimethylamine N-oxide (TMAO), a gut-liver co-metabolite, is frequently discussed. Changes in TMAO levels correlate with cardiometabolic risk and low-grade inflammation,78,79 potentially influencing the systemic inflammatory set point in OA by affecting endothelial/lipid metabolism and inflammatory responsiveness. Meanwhile, intermediate metabolites (lactate and succinate) can accumulate under specific microbial compositions and metabolic conditions, functioning as immunometabolic signals that modulate myeloid cell inflammatory phenotypes and tissue reactivity.80,81 Therefore, metabolite remodeling caused by gut dysbiosis is characterized by decreased immune tolerance-related metabolites and enhanced pro-inflammatory metabolic pathways, collectively contributing to systemic inflammation in OA and facilitating subsequent local inflammatory amplification and immunometabolic crosstalk.15,45 Systemic Exposure of Gut-Derived Inflammatory Signals and PRR-Mediated Joint Inflammation Initiation When homeostatic immunomodulatory signals diminish and barriers (mucus layer, epithelial tight junctions, IgA) weaken, gut-derived inflammatory signals readily enter circulation, providing upstream stimuli for PRR-mediated innate immune activation. Increased intestinal permeability leads to elevated circulating endotoxin and other MAMPs, important contributors to systemic low-grade inflammation.19,21,22 Additionally, particulate or structural signals such as bacterial outer membrane vesicles, peptidoglycan fragments, and microbial nucleic acid fragments may enter circulation under barrier impairment, altering the exposure spectrum of gut-derived stimuli.15 Circulating gut-derived signals are recognized by pattern-recognition receptors (PRRs) expressed on synovial macrophages, fibroblast-like synoviocytes (FLS), and chondrocytes. Among these, the TLR4 pathway is most representative. LPS signals are primarily sensed via the TLR4 co-receptor complex, activating NF-κB and mitogen-activated protein kinase (MAPK) cascades through the myeloid differentiation primary response 88 (MyD88)-dependent pathway, thus increasing inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-C motif chemokine ligand 2 (CCL2).24–26 Toll-like receptor 2 (TLR2) also participates in recognizing certain bacterial components. These mediators enhance inflammatory responsiveness of synovial macrophages and FLS, promote immune cell recruitment, and activate chondrocyte catabolic programs involving matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), thereby perpetuating synovitis and exacerbating cartilage degradation. In addition to the TLR4-NF-κB/MAPK pathway, the NLR family pyrin domain containing 3 (NLRP3) inflammasome represents another crucial node for PRR-related inflammatory amplification.27,30 TLR4–NF-κB signaling upregulates NLRP3 and the precursor proteins pro-interleukin-1 beta (pro-IL-1β) and pro-interleukin-18 (pro-IL-18), while elevated mitochondrial reactive oxygen species (ROS), K+ efflux, or lysosomal damage further activate NLRP3, promoting the maturation and release of IL-1β and IL-18 and thereby amplifying inflammation and tissue injury. Intracellular PRR pathways involving nucleotide-binding oligomerization domain-containing protein 1 (NOD1) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) may synergize with Toll-like receptor (TLR) signaling, thereby maintaining inflammatory responses. In joints, synovial myeloid cells (especially monocytes/macrophages) and FLS are primary effectors integrating PRR signals. By analogy with oral–gut–immune frameworks in inflammatory arthritides, sustained exposure to gut-derived inflammatory signals, increased cytokine burden, and accumulated matrix degradation products, also known as damage-associated molecular patterns (DAMPs), may reinforce synovial myeloid-cell and FLS activation. However, because direct OA-specific evidence for this route remains limited, this mechanism should be regarded as hypothesis-generating and requires further validation in OA patient-derived tissues and experimental OA models.69,82 Chondrocytes also exhibit enhanced responses to PRR-related inflammatory stimuli, upregulating catabolic processes (MMPs/ADAMTS), thereby coupling local inflammation with structural degeneration. Myeloid cells and bone remodeling cells may participate in this inflammation-remodeling loop, but their contributions in OA phenotypes require further investigation. Overall, gut-derived MAMPs and related signals may sustain inflammatory amplification through pathways such as TLR4–NF-κB/MAPK and the NLRP3 inflammasome, thereby lowering joint inflammatory thresholds and linking systemic gut-derived inputs to local structural remodeling. Crucially, PRR-mediated inflammation may further initiate immunometabolic crosstalk through metabolic reprogramming of immune and structural cells.16,83 Metabolic Tissue Inflammatory Amplification and Maintenance of Systemic Low-Grade Inflammation When prolonged systemic exposure to gut-derived molecules combines with metabolic abnormalities, inflammatory stimuli can affect metabolic tissues (eg, adipose tissue, liver, skeletal muscle). This process induces or exacerbates systemic low-grade inflammation.15 Furthermore, aging-related immunosenescence and accumulation of senescent cells, characterized by the senescence-associated secretory phenotype (SASP), can sustain low-grade inflammation and impair tissue repair capacity, promoting chronic inflammation and structural degeneration.84–86 These tissue-level inflammatory and metabolic disturbances synergistically elevate circulating inflammatory mediators and maintain a pro-inflammatory primed state in myeloid cells, creating a systemic background conducive to persistent inflammation.15 Under these conditions, the body’s responsiveness to gut-derived MAMPs (eg, LPS) is enhanced, triggering PRR-mediated innate immune amplification and maintaining systemic low-grade joint inflammation. Concurrently, this systemic inflammatory-metabolic background perpetuates synovitis and disrupts cartilage homeostasis by influencing synovial immune cell recruitment and activation, enhancing chondrocyte inflammatory responsiveness, and promoting matrix degradation programs.14,15 Existing evidence indicates that OA-related intestinal alterations consistently reflect remodeling of microbial functional outputs, impaired intestinal barrier function, and increased gut-derived inflammatory input, rather than single taxonomic fluctuations. Animal models provide causal support for several key associations, particularly through studies using germ-free animals, fecal microbiota transplantation (FMT), and metabolite-receptor pathway validation. However, the strength and OA-specificity of evidence supporting different components of the gut–joint axis are heterogeneous. Therefore, we graded the major mechanistic links according to evidence type, including population association, animal causal evidence, in vitro mechanistic evidence, translational intervention evidence, mixed evidence, and extrapolated/hypothetical evidence. This evidence-grading framework aims to distinguish direct OA-specific findings from mechanisms inferred from rheumatoid arthritis, other inflammatory arthritides, oral–gut–immune frameworks, or broader immunometabolic studies (Table 1). Table 1Evidence Grading of Gut–Joint Axis-Related Mechanisms in OAMechanistic ComponentRole in OA PathogenesisSupporting EvidenceEvidence LevelOA-Specificity and InterpretationMicrobial functional remodelingOA-associated gut alterations involve changes in microbial function, metabolite profiles, pain, inflammation, and structural severityHuman studies linked gut microbiome-related metabolites and microbial signatures with symptomatic hand OA or knee OA; systematic reviews also support microbiome alterations in OA patients33,87,88Population associationDirect OA evidence. Supports association, but causality remains uncertainReduction in homeostasis-related metabolitesReduced or altered SCFAs, BAs, and tryptophan-related metabolites may weaken barrier support and anti-inflammatory signalingHuman metabolite studies linked gut microbiota-related metabolites with symptomatic hand OA; other studies connected tryptophan metabolites, BA metabolism, and GUDCA/UDCA-related pathways with OA phenotypes40,63,77,87Population association/mechanistic evidencePartial direct OA evidence. Stronger for association than for complete causal pathwayIntestinal barrier dysfunction and translocation markersIncreased intestinal permeability may increase systemic exposure to gut-derived inflammatory signalsDIGICOD-related evidence reported elevated LBP and ZRP in erosive hand osteoarthritis (EHOA); ZRP correlated with radiographic structural damage and LBP with erosive joint burden54Population associationDirect OA evidence. Useful as clinical association, but marker specificity remains limitedIncreased exposure to gut-derived MAMPsElevated endotoxin-related burden may amplify PRR-mediated inflammation and lower joint inflammatory thresholdBarrier-related studies used LBP as a surrogate indicator; FMT studies showed increased intestinal permeability, endotoxemia, systemic low-grade inflammation, and aggravated post-injury OA54,89Population association/animal causal evidenceDirect and OA-related evidence. Stronger when supported by FMT modelsMicrobiota involvement in post-injury OA amplificationAbsence of microbiota reduces OA severity after joint injuryGerm-free mice with DMM-induced OA showed reduced cartilage damage and osteophyte formation90Animal causal evidenceDirect OA-related animal evidence. Supports microbiota as an amplifier of post-injury OATransferability of microbiota-related OA susceptibilityHuman-derived or metabolically unfavorable microbiota can increase OA susceptibility in recipient animalsFMT from metabolically compromised human donors accelerated OA in mice and supported a two-hit model involving unfavorable microbiota and joint injury89Animal causal evidenceStrong OA-related causal evidence in animals. Human causality still requires validationMicrobiota metabolite–receptor axesMicrobial metabolites may regulate OA through receptor-mediated immune-metabolic pathwaysGUDCA/UDCA-associated intestinal FXR–GLP-1 axis was implicated in OA regulation; GPR43 inhibition in macrophages alleviated OA by suppressing M1 polarization and ROS production; prebiotic intervention improved obesity-associated OA features77,91,92Animal causal/in vitro mechanistic evidenceDirect or partial OA evidence. Candidate mechanistic pathway requiring further clinical validationLPS–TLR4–NF-κB/MAPK signalingGut-derived MAMPs may activate PRR signaling in synovial macrophages, FLS, and chondrocytesOA-related studies support TLR4/NF-κB/MAPK activation and downstream inflammatory cytokine and catabolic mediator production24–26In vitro mechanistic/animal evidenceRelatively strong OA-specific mechanistic evidenceNLRP3 inflammasome activationInflammasome activation amplifies IL-1β/IL-18 release, synovitis, and cartilage catabolismOA-related studies support NLRP3 inflammasome involvement in inflammatory amplification and tissue degeneration27,30In vitro mechanistic/animal evidenceRelatively strong OA-specific mechanistic evidenceChondrocyte metabolic reprogrammingGlucose, lipid, and amino acid metabolic abnormalities contribute to cartilage catabolism and cell stressOA studies reported context-dependent PFKFB3 effects, FAO–acetyl-CoA–SOX9/MMP13/ADAMTS7 regulation, and glutathione/GPX4-related ferroptosis mechanisms93–99In vitro mechanistic/animal evidenceDirect OA mechanistic evidence. Stronger for local joint metabolism than for gut-derived causalitySynovial macrophage metabolic reprogrammingGlycolysis, lactate-related modification, lipid handling, and amino acid metabolism may stabilize inflammatory macrophage phenotypesOA-related evidence supports macrophage glycolysis and lactylation in synovitis; broader immunometabolic evidence supports lipid and amino-acid regulation of macrophage polarization93,100–106In vitro mechanistic/mixed evidencePartial OA evidence. Some metabolic principles are extrapolated from broader immunometabolismFLS metabolic reprogrammingGlycolytic FLS may acquire proliferative, migratory, and pro-inflammatory phenotypesOA synovial studies reported enhanced glycolysis, PDK/PDHA1-related metabolic shifts, and inflammatory FLS activation107–111In vitro mechanistic evidenceDirect OA-related synovial evidence, but gut-derived upstream linkage remains partly inferredTh17/Treg imbalance and adaptive immune modulationChronic inflammation and metabolic stress may favor Th17 responses and impair Treg-mediated resolutionOA studies support Th17/Treg imbalance, while metabolic interpretation of T-cell subset stability is supported by broader immunometabolic literature112–120Mixed evidencePartial OA evidence. Immune imbalance is supported in OA, but gut-derived metabolic causality remains incompleteSynovium–IPFP–cartilage/subchondral bone crosstalkLocal tissue crosstalk may amplify inflammatory and metabolic stress within the jointOA studies implicate IPFP-derived adipokines, cytokines, lipid mediators, oxidative stress, ferroptosis, and subchondral bone remodeling; RA single-cell studies provide comparator frameworks for fibroblast/myeloid amplification121–127Mixed OA evidence/comparator evidenceMostly OA-specific for IPFP-joint crosstalk; RA comparator evidence should be interpreted cautiouslyOral–gut–immune and inflammatory arthritis analogiesSome immune amplification routes are inferred from RA, inflammatory arthritis, or oral–gut–immune frameworksOral–gut–immune and inflammatory arthritis frameworks suggest possible links among microbial exposure, systemic immune priming, and synovial inflammation69,82,122,123Extrapolated/hypothetical evidenceNot direct OA evidence. Should be presented as hypothesis-generatingTrained immunity-like and epigenetic-locking mechanismsPersistent PRR stimulation and metabolic stress may induce durable inflammatory memory-like statesCurrent OA-specific evidence is limited; the concept is mainly inferred from broader immunometabolic and inflammatory arthritis literature118–120,128–132Extrapolated/hypothetical evidenceHypothesis-generating. Requires direct validation in OA synovial cells, chondrocytes, and patient-derived tissuesMetformin and GLP-1-related metabolic interventionsSystemic metabolic modulation may improve pain or inflammatory-metabolic OA phenotypesMetformin improved pain in overweight or obese patients with knee OA; GLP-1 receptor agonist-related studies suggest potential value in OA populations with metabolic disorders133–136Translational intervention evidenceClinically relevant, especially for metabolic-inflammatory OA. Structural disease-modifying effects still require long-term validationNatural products and phytochemicalsMulti-node modulation may affect microbiota, barrier function, inflammation, oxidative stress, and cartilage protectionPolysaccharides, berberine, curcumin, resveratrol, and quercetin have been linked to gut microbiota modulation, AMPK activation, anti-inflammatory effects, and cartilage-protective outcomes137–148Animal/clinical/mechanistic mixed evidenceSupportive but heterogeneous evidence. Should be interpreted as adjunctive and mechanism-generating rather than definitiveNotes: Evidence levels were defined as follows. Population association: evidence from human observational, cohort, microbiome, or metabolite-association studies. Animal causal evidence: evidence from germ-free, fecal microbiota transplantation, diet-induced, or surgically induced OA models. In vitro mechanistic evidence: evidence from cell-based experiments using chondrocytes, synovial macrophages, fibroblast-like synoviocytes, or related immune cells. Translational intervention evidence: evidence from clinical or preclinical therapeutic intervention studies. Mixed evidence: evidence supported by more than one evidence type but not uniformly validated across OA-specific systems. Extrapolated/hypothetical evidence: mechanisms mainly inferred from rheumatoid arthritis, other inflammatory arthritides, oral–gut–immune frameworks, or broader immunometabolic literature rather than directly validated in OA.Abbreviations: acetyl-CoA, acetyl coenzyme A; ADAMTS7, a disintegrin and metalloproteinase with thrombospondin motifs 7; AMPK, AMP-activated protein kinase; BAs, bile acids; DIGICOD, DIGItal COhort Design; DMM, destabilization of the medial meniscus; EHOA, erosive hand osteoarthritis; FAO, fatty acid oxidation; FLS, fibroblast-like synoviocytes; FMT, fecal microbiota transplantation; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; GPX4, glutathione peroxidase 4; GPR43, G protein-coupled receptor 43; GUDCA, glycoursodeoxycholic acid; IL-1β, interleukin-1 beta; IL-18, interleukin-18; IPFP, infrapatellar fat pad; LBP, lipopolysaccharide-binding protein; LPS, lipopolysaccharide; M1, pro-inflammatory macrophage phenotype; MAMPs, microbial-associated molecular patterns; MAPK, mitogen-activated protein kinase; MMP13, matrix metalloproteinase 13; NF-κB, nuclear factor kappa-B; NLRP3, NLR family pyrin domain containing 3; OA, osteoarthritis; PDHA1, pyruvate dehydrogenase E1 subunit alpha 1; PDK, pyruvate dehydrogenase kinase; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; PRR, pattern-recognition receptor; RA, rheumatoid arthritis; ROS, reactive oxygen species; SCFAs, short-chain fatty acids; SOX9, SRY-box transcription factor 9; Th17, T helper 17; TLR4, Toll-like receptor 4; Treg, regulatory T cell; UDCA, ursodeoxycholic acid; ZRP, zonulin-related protein. Table 1Evidence Grading of Gut–Joint Axis-Related Mechanisms in OAMechanistic ComponentRole in OA PathogenesisSupporting EvidenceEvidence LevelOA-Specificity and InterpretationMicrobial functional remodelingOA-associated gut alterations involve changes in microbial function, metabolite profiles, pain, inflammation, and structural severityHuman studies linked gut microbiome-related metabolites and microbial signatures with symptomatic hand OA or knee OA; systematic reviews also support microbiome alterations in OA patients33,87,88Population associationDirect OA evidence. Supports association, but causality remains uncertainReduction in homeostasis-related metabolitesReduced or altered SCFAs, BAs, and tryptophan-related metabolites may weaken barrier support and anti-inflammatory signalingHuman metabolite studies linked gut microbiota-related metabolites with symptomatic hand OA; other studies connected tryptophan metabolites, BA metabolism, and GUDCA/UDCA-related pathways with OA phenotypes40,63,77,87Population association/mechanistic evidencePartial direct OA evidence. Stronger for association than for complete causal pathwayIntestinal barrier dysfunction and translocation markersIncreased intestinal permeability may increase systemic exposure to gut-derived inflammatory signalsDIGICOD-related evidence reported elevated LBP and ZRP in erosive hand osteoarthritis (EHOA); ZRP correlated with radiographic structural damage and LBP with erosive joint burden54Population associationDirect OA evidence. Useful as clinical association, but marker specificity remains limitedIncreased exposure to gut-derived MAMPsElevated endotoxin-related burden may amplify PRR-mediated inflammation and lower joint inflammatory thresholdBarrier-related studies used LBP as a surrogate indicator; FMT studies showed increased intestinal permeability, endotoxemia, systemic low-grade inflammation, and aggravated post-injury OA54,89Population association/animal causal evidenceDirect and OA-related evidence. Stronger when supported by FMT modelsMicrobiota involvement in post-injury OA amplificationAbsence of microbiota reduces OA severity after joint injuryGerm-free mice with DMM-induced OA showed reduced cartilage damage and osteophyte formation90Animal causal evidenceDirect OA-related animal evidence. Supports microbiota as an amplifier of post-injury OATransferability of microbiota-related OA susceptibilityHuman-derived or metabolically unfavorable microbiota can increase OA susceptibility in recipient animalsFMT from metabolically compromised human donors accelerated OA in mice and supported a two-hit model involving unfavorable microbiota and joint injury89Animal causal evidenceStrong OA-related causal evidence in animals. Human causality still requires validationMicrobiota metabolite–receptor axesMicrobial metabolites may regulate OA through receptor-mediated immune-metabolic pathwaysGUDCA/UDCA-associated intestinal FXR–GLP-1 axis was implicated in OA regulation; GPR43 inhibition in macrophages alleviated OA by suppressing M1 polarization and ROS production; prebiotic intervention improved obesity-associated OA features77,91,92Animal causal/in vitro mechanistic evidenceDirect or partial OA evidence. Candidate mechanistic pathway requiring further clinical validationLPS–TLR4–NF-κB/MAPK signalingGut-derived MAMPs may activate PRR signaling in synovial macrophages, FLS, and chondrocytesOA-related studies support TLR4/NF-κB/MAPK activation and downstream inflammatory cytokine and catabolic mediator production24–26In vitro mechanistic/animal evidenceRelatively strong OA-specific mechanistic evidenceNLRP3 inflammasome activationInflammasome activation amplifies IL-1β/IL-18 release, synovitis, and cartilage catabolismOA-related studies support NLRP3 inflammasome involvement in inflammatory amplification and tissue degeneration27,30In vitro mechanistic/animal evidenceRelatively strong OA-specific mechanistic evidenceChondrocyte metabolic reprogrammingGlucose, lipid, and amino acid metabolic abnormalities contribute to cartilage catabolism and cell stressOA studies reported context-dependent PFKFB3 effects, FAO–acetyl-CoA–SOX9/MMP13/ADAMTS7 regulation, and glutathione/GPX4-related ferroptosis mechanisms93–99In vitro mechanistic/animal evidenceDirect OA mechanistic evidence. Stronger for local joint metabolism than for gut-derived causalitySynovial macrophage metabolic reprogrammingGlycolysis, lactate-related modification, lipid handling, and amino acid metabolism may stabilize inflammatory macrophage phenotypesOA-related evidence supports macrophage glycolysis and lactylation in synovitis; broader immunometabolic evidence supports lipid and amino-acid regulation of macrophage polarization93,100–106In vitro mechanistic/mixed evidencePartial OA evidence. Some metabolic principles are extrapolated from broader immunometabolismFLS metabolic reprogrammingGlycolytic FLS may acquire proliferative, migratory, and pro-inflammatory phenotypesOA synovial studies reported enhanced glycolysis, PDK/PDHA1-related metabolic shifts, and inflammatory FLS activation107–111In vitro mechanistic evidenceDirect OA-related synovial evidence, but gut-derived upstream linkage remains partly inferredTh17/Treg imbalance and adaptive immune modulationChronic inflammation and metabolic stress may favor Th17 responses and impair Treg-mediated resolutionOA studies support Th17/Treg imbalance, while metabolic interpretation of T-cell subset stability is supported by broader immunometabolic literature112–120Mixed evidencePartial OA evidence. Immune imbalance is supported in OA, but gut-derived metabolic causality remains incompleteSynovium–IPFP–cartilage/subchondral bone crosstalkLocal tissue crosstalk may amplify inflammatory and metabolic stress within the jointOA studies implicate IPFP-derived adipokines, cytokines, lipid mediators, oxidative stress, ferroptosis, and subchondral bone remodeling; RA single-cell studies provide comparator frameworks for fibroblast/myeloid amplification121–127Mixed OA evidence/comparator evidenceMostly OA-specific for IPFP-joint crosstalk; RA comparator evidence should be interpreted cautiouslyOral–gut–immune and inflammatory arthritis analogiesSome immune amplification routes are inferred from RA, inflammatory arthritis, or oral–gut–immune frameworksOral–gut–immune and inflammatory arthritis frameworks suggest possible links among microbial exposure, systemic immune priming, and synovial inflammation69,82,122,123Extrapolated/hypothetical evidenceNot direct OA evidence. Should be presented as hypothesis-generatingTrained immunity-like and epigenetic-locking mechanismsPersistent PRR stimulation and metabolic stress may induce durable inflammatory memory-like statesCurrent OA-specific evidence is limited; the concept is mainly inferred from broader immunometabolic and inflammatory arthritis literature118–120,128–132Extrapolated/hypothetical evidenceHypothesis-generating. Requires direct validation in OA synovial cells, chondrocytes, and patient-derived tissuesMetformin and GLP-1-related metabolic interventionsSystemic metabolic modulation may improve pain or inflammatory-metabolic OA phenotypesMetformin improved pain in overweight or obese patients with knee OA; GLP-1 receptor agonist-related studies suggest potential value in OA populations with metabolic disorders133–136Translational intervention evidenceClinically relevant, especially for metabolic-inflammatory OA. Structural disease-modifying effects still require long-term validationNatural products and phytochemicalsMulti-node modulation may affect microbiota, barrier function, inflammation, oxidative stress, and cartilage protectionPolysaccharides, berberine, curcumin, resveratrol, and quercetin have been linked to gut microbiota modulation, AMPK activation, anti-inflammatory effects, and cartilage-protective outcomes137–148Animal/clinical/mechanistic mixed evidenceSupportive but heterogeneous evidence. Should be interpreted as adjunctive and mechanism-generating rather than definitiveNotes: Evidence levels were defined as follows. Population association: evidence from human observational, cohort, microbiome, or metabolite-association studies. Animal causal evidence: evidence from germ-free, fecal microbiota transplantation, diet-induced, or surgically induced OA models. In vitro mechanistic evidence: evidence from cell-based experiments using chondrocytes, synovial macrophages, fibroblast-like synoviocytes, or related immune cells. Translational intervention evidence: evidence from clinical or preclinical therapeutic intervention studies. Mixed evidence: evidence supported by more than one evidence type but not uniformly validated across OA-specific systems. Extrapolated/hypothetical evidence: mechanisms mainly inferred from rheumatoid arthritis, other inflammatory arthritides, oral–gut–immune frameworks, or broader immunometabolic literature rather than directly validated in OA.Abbreviations: acetyl-CoA, acetyl coenzyme A; ADAMTS7, a disintegrin and metalloproteinase with thrombospondin motifs 7; AMPK, AMP-activated protein kinase; BAs, bile acids; DIGICOD, DIGItal COhort Design; DMM, destabilization of the medial meniscus; EHOA, erosive hand osteoarthritis; FAO, fatty acid oxidation; FLS, fibroblast-like synoviocytes; FMT, fecal microbiota transplantation; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; GPX4, glutathione peroxidase 4; GPR43, G protein-coupled receptor 43; GUDCA, glycoursodeoxycholic acid; IL-1β, interleukin-1 beta; IL-18, interleukin-18; IPFP, infrapatellar fat pad; LBP, lipopolysaccharide-binding protein; LPS, lipopolysaccharide; M1, pro-inflammatory macrophage phenotype; MAMPs, microbial-associated molecular patterns; MAPK, mitogen-activated protein kinase; MMP13, matrix metalloproteinase 13; NF-κB, nuclear factor kappa-B; NLRP3, NLR family pyrin domain containing 3; OA, osteoarthritis; PDHA1, pyruvate dehydrogenase E1 subunit alpha 1; PDK, pyruvate dehydrogenase kinase; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; PRR, pattern-recognition receptor; RA, rheumatoid arthritis; ROS, reactive oxygen species; SCFAs, short-chain fatty acids; SOX9, SRY-box transcription factor 9; Th17, T helper 17; TLR4, Toll-like receptor 4; Treg, regulatory T cell; UDCA, ursodeoxycholic acid; ZRP, zonulin-related protein. Evidence Grading of Gut–Joint Axis-Related Mechanisms in OA Notes: Evidence levels were defined as follows. Population association: evidence from human observational, cohort, microbiome, or metabolite-association studies. Animal causal evidence: evidence from germ-free, fecal microbiota transplantation, diet-induced, or surgically induced OA models. In vitro mechanistic evidence: evidence from cell-based experiments using chondrocytes, synovial macrophages, fibroblast-like synoviocytes, or related immune cells. Translational intervention evidence: evidence from clinical or preclinical therapeutic intervention studies. Mixed evidence: evidence supported by more than one evidence type but not uniformly validated across OA-specific systems. Extrapolated/hypothetical evidence: mechanisms mainly inferred from rheumatoid arthritis, other inflammatory arthritides, oral–gut–immune frameworks, or broader immunometabolic literature rather than directly validated in OA. Abbreviations: acetyl-CoA, acetyl coenzyme A; ADAMTS7, a disintegrin and metalloproteinase with thrombospondin motifs 7; AMPK, AMP-activated protein kinase; BAs, bile acids; DIGICOD, DIGItal COhort Design; DMM, destabilization of the medial meniscus; EHOA, erosive hand osteoarthritis; FAO, fatty acid oxidation; FLS, fibroblast-like synoviocytes; FMT, fecal microbiota transplantation; FXR, farnesoid X receptor; GLP-1, glucagon-like peptide-1; GPX4, glutathione peroxidase 4; GPR43, G protein-coupled receptor 43; GUDCA, glycoursodeoxycholic acid; IL-1β, interleukin-1 beta; IL-18, interleukin-18; IPFP, infrapatellar fat pad; LBP, lipopolysaccharide-binding protein; LPS, lipopolysaccharide; M1, pro-inflammatory macrophage phenotype; MAMPs, microbial-associated molecular patterns; MAPK, mitogen-activated protein kinase; MMP13, matrix metalloproteinase 13; NF-κB, nuclear factor kappa-B; NLRP3, NLR family pyrin domain containing 3; OA, osteoarthritis; PDHA1, pyruvate dehydrogenase E1 subunit alpha 1; PDK, pyruvate dehydrogenase kinase; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; PRR, pattern-recognition receptor; RA, rheumatoid arthritis; ROS, reactive oxygen species; SCFAs, short-chain fatty acids; SOX9, SRY-box transcription factor 9; Th17, T helper 17; TLR4, Toll-like receptor 4; Treg, regulatory T cell; UDCA, ursodeoxycholic acid; ZRP, zonulin-related protein. Immunometabolic Crosstalk Driven by the Gut-Joint Axis and Its Molecular Mechanisms in OA Immunometabolic crosstalk refers to a process in which immune activation (eg, PRR-mediated inflammatory signaling) and metabolic stress (eg, gut-derived metabolites, local hypoxia, acidosis) synergistically induce metabolic reprogramming in joint cells. This reprogramming, in turn, stabilizes and amplifies immune abnormalities, ultimately forming a positive feedback loop.28,128 From the perspective of the gut-joint axis, this positive feedback loop, driven by gut-derived signals, constitutes the core mechanism driving OA progression.15,149 Under systemic exposure to gut-derived molecules and systemic low-grade inflammation, the load of MAMPs recognized by PRRs increases in the joint microenvironment. Synovial myeloid cells, FLS, and chondrocytes become activated, triggering pro-inflammatory cascades.30 Under repeated stimulation and metabolic stress, this inflammatory input induces immune reprogramming and creates a positive feedback loop through metabolic and transcriptional/epigenetic remodeling. This shifts the joint from homeostasis toward a chronic pro-inflammatory and catabolic state, promoting structural degeneration.83,150 The following sections outline the molecular cascades and amplification loops of PRR signaling within the joint and explain how immunometabolic crosstalk drives chronic inflammation and tissue degeneration. The detailed molecular networks and pathways governing this immunometabolic crosstalk are comprehensively depicted in Figure 2. Figure 2Immunometabolic crosstalk linking gut-derived inflammatory input to joint tissue remodeling in OA. This schematic focuses on downstream molecular and cellular events within OA-relevant joint tissues. Gut-derived MAMPs and inflammatory mediators may activate PRR-dependent pathways, including TLR4–NF-κB/MAPK signaling and the NLRP3 inflammasome, in synovial macrophages, fibroblast-like synoviocytes, and chondrocytes. These inflammatory signals interact with metabolic stressors such as glycolytic activation, lactate accumulation, mitochondrial ROS, altered lipid metabolism, and amino acid metabolic imbalance, thereby sustaining immunometabolic crosstalk and contributing to synovial inflammation, cartilage matrix remodeling, and subchondral bone changes. The one-carbon metabolism/epigenetic-locking node is labeled as proposed/hypothetical because direct OA-specific evidence remains limited.The schematic shows immunometabolic interactions in osteoarthritis, initiated by persistent inflammation and metabolic stress. Additional driver inputs include mechanical stress, microdamage, hypoxia, and oxidative stress, which trigger inflammatory metabolic rewiring characterized by increased glycolysis, mitochondrial dysfunction, and flux repartitioning. NADPH supply and redox buffering are linked to metabolic persistence, while substrate limitation alters glucose, amino acid, and arginine metabolism. Proposed one-carbon metabolism and metabolic-epigenetic locking involve altered methyl-donor availability and histone methylation. Downstream pathways include mitochondrial ROS and NLRP3 inflammasome activation, succinate-mediated HIF-1α stabilization and increased IL-1β transcription, and lactate accumulation and acidosis that promote inflammatory and angiogenic programs. These pathways converge on increased inflammatory effector output, including cytokines, chemokines, and catabolic programs. Extracellular matrix degradation releases DAMPs, reinforcing a closed positive feedback loop that sustains synovitis, transcriptional reinforcement, and inflammatory amplification.OA immunometabolic crosstalk: pathways from input to inflammatory output, including feedback loops. Immunometabolic crosstalk linking gut-derived inflammatory input to joint tissue remodeling in OA. This schematic focuses on downstream molecular and cellular events within OA-relevant joint tissues. Gut-derived MAMPs and inflammatory mediators may activate PRR-dependent pathways, including TLR4–NF-κB/MAPK signaling and the NLRP3 inflammasome, in synovial macrophages, fibroblast-like synoviocytes, and chondrocytes. These inflammatory signals interact with metabolic stressors such as glycolytic activation, lactate accumulation, mitochondrial ROS, altered lipid metabolism, and amino acid metabolic imbalance, thereby sustaining immunometabolic crosstalk and contributing to synovial inflammation, cartilage matrix remodeling, and subchondral bone changes. The one-carbon metabolism/epigenetic-locking node is labeled as proposed/hypothetical because direct OA-specific evidence remains limited. Diet, obesity, aging, or antibiotic-induced gut dysbiosis may impair barrier integrity, reduce protective microbial metabolites, and increase systemic exposure to LPS and other MAMPs. These signals activate PRR-dependent inflammatory pathways in joint tissues and amplify immunometabolic crosstalk, thereby linking gut-derived inflammatory inputs to synovial inflammation, cartilage matrix remodeling, subchondral bone changes, and OA progression. The infrapatellar fat pad (IPFP) may further exacerbate local inflammatory and metabolic imbalance. Core Mechanisms of Metabolic Reprogramming Metabolic abnormalities in OA joints are not confined to a single cell type or pathway; rather, they represent metabolic reprogramming of multiple immune and structural cells. This reprogramming results from sustained inflammation, hypoxia, acidosis, oxidative stress, and nutrient fluctuations.28,29 These metabolic shifts not only affect energy supply but also shape cell phenotypes, sustain inflammation, and drive tissue degeneration. They are continuously influenced by gut-derived inflammatory signals and systemic low-grade inflammation.14,15,19 OA-related metabolic reprogramming primarily involves glucose, lipid, and amino acid metabolism. Among joint cells, synovial macrophages, FLS, and chondrocytes provide the most substantial evidence of such changes. Glucose Glucose metabolic abnormalities are extensively studied in OA and primarily characterized by enhanced glycolysis, lactate accumulation, and impaired oxidative phosphorylation.151,152 Because cartilage is naturally hypoxic and avascular, chondrocytes typically rely on glycolysis. However, inflammatory stimuli, mechanical stress, and mitochondrial dysfunction further shift glucose metabolism away from homeostasis toward abnormal activation, impacting ATP supply, redox balance, and matrix metabolism.29 Reviews indicate that glucose metabolism disorders promote chondrocyte hypertrophic changes and extracellular matrix degradation, closely associated with OA progression. Relevant molecules include glucose transporter 1 (GLUT1), hexokinase 2 (HK2), lactate dehydrogenase A (LDHA), pyruvate kinase M2 (PKM2), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), and regulatory pathways such as hypoxia-inducible factor 1-alpha (HIF-1α) and NF-κB.29 Notably, glucose metabolism in OA may be context-dependent. For instance, studies suggest decreased PFKFB3 in OA cartilage impairs DNA damage repair and accelerates cellular senescence. Thus, glucose metabolism changes in OA are dynamic rather than uniformly enhanced.93–95 Lipids Lipid metabolism abnormalities constitute another critical aspect of metabolic reprogramming in OA, involving imbalances in fatty acid oxidation, synthesis, and lipid mediator production.29 Lipid metabolic changes not only affect energy supply and membrane biosynthesis but also influence transcriptional regulation and epigenetic modulation through acetyl coenzyme A (acetyl-CoA) accumulation, lipid signaling molecules, and inflammatory mediator release. In obesity- or metabolic disorder-related OA, these changes significantly sustain low-grade inflammation, enhance catabolism, and disrupt bone-cartilage remodeling.29 Recent studies directly link enhanced fatty acid oxidation in chondrocytes with acetyl-CoA accumulation, hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha acetylation, decreased AMP-activated protein kinase (AMPK) activity, SRY-box transcription factor 9(SOX9) degradation, and increased expression of matrix metalloproteinase 13(MMP13) and a disintegrin and metalloproteinase with thrombospondin motifs 7(ADAMTS7). This evidence underscores lipid metabolic reprogramming as a direct contributor to OA progression rather than merely a secondary event.96 Amino Acids Amino acid metabolic reprogramming mainly involves arginine, glutamine, and glutathione metabolism.129,130 Arginine metabolism through inducible nitric oxide synthase (iNOS) and arginase influences nitric oxide production, oxidative/nitrosative stress, and inflammation persistence. Glutamine metabolism closely interacts with tricarboxylic acid (TCA) cycle anaplerosis, stress adaptation, and inflammatory signaling. Additionally, reduced glutathione synthesis and impaired glutathione peroxidase 4 (GPX4) activity promote lipid peroxidation and susceptibility to ferroptosis, contributing to chondrocyte damage and OA progression. OA research indicates that glutamine metabolism modulates chondrocyte inflammatory responses: glutamine deficiency reduces inflammatory output by inhibiting NF-κB and promoting autophagy. Direct evidence on one-carbon metabolism in OA remains limited and currently serves primarily as a supplementary mechanism potentially linked to metabolic-epigenetic regulation.131,132 Metabolic Reprogramming of OA-Related Cells Synovial Macrophages Under inflammatory stimuli, hypoxia, and metabolic stress, macrophages typically shift from oxidative metabolism to glycolysis. This shift often coincides with maintaining a pro-inflammatory phenotype.100,101,128 Studies indicate that in hyperglycemia-related OA, high glucose enhances glycolysis in synovial macrophages, leading to lactate accumulation, which drives lactylation of integrin alpha M at K575. This modification alters protein conformation, impairs apoptotic cell recognition, and compromises macrophage efferocytosis, thereby amplifying synovitis and OA progression.93 Thus, enhanced glycolysis in OA is not merely an adaptive energy response but directly contributes to macrophage dysfunction and chronic inflammation. Additionally, the glycolytic shift coincides with mitochondrial rearrangements, such as succinate and ROS accumulation, further promoting pro-inflammatory transcriptional programs and inflammasome activation, integrating metabolic and inflammatory pathways.80,102 Lipid metabolism is increasingly recognized as a determinant of myeloid cell function, including in macrophages and dendritic cells.103 Immunometabolic research indicates that pro-inflammatory macrophages generally favor glycolysis and fatty acid synthesis, while inflammation-resolving phenotypes depend on fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS); macrophage polarization is tightly coupled to such metabolic switches.104 Nuclear receptors and lipid handling regulators such as Peroxisome proliferator-activated receptor gamma, carnitine palmitoyltransferase 1A, and the fatty acid transporter cluster of differentiation 36 are commonly implicated in this metabolic balance. Direct OA-focused studies on macrophage lipid metabolism remain limited compared with glycolysis, but metabolic OA and obesity-related inflammation suggest abnormal lipid loads likely contribute to sustained macrophage activation.105 Regarding amino acid metabolism, arginine flux through inducible nitric oxide synthase (iNOS) and arginase 1, together with glutamine metabolism involving glutaminase, glutamate dehydrogenase, and alpha-ketoglutarate, critically influences macrophage phenotypes.106 Increased arginine flux through the iNOS pathway enhances nitric oxide production and oxidative/nitrosative stress. Glutamine metabolism supports oxidative metabolism and epigenetic regulation.129 Although direct evidence in OA synovial macrophages is scarce, these metabolic mechanisms provide a framework to explain persistent pro-inflammatory macrophage activation, elevated oxidative stress, and insufficient inflammation resolution observed in OA.83 FLS FLS represent another key cell population in OA synovial lesions. Under normal conditions, FLS mainly maintain synovial homeostasis and provide matrix support. However, sustained inflammatory stimulation and abnormal mechanical environments cause FLS to gradually adopt a highly proliferative, migratory, and pro-inflammatory phenotype.107 Studies indicate that proliferative podoplanin-positive and thymocyte differentiation antigen 1-positive (PDPN+THY1+) FLS in OA synovium exhibit significantly enhanced glycolysis, characterized by increased expression of pyruvate dehydrogenase kinase (PDK), particularly PDK3, and phosphorylated pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1). Overexpression of PDK limits pyruvate entry into mitochondrial oxidative pathways, shifting metabolism toward glycolysis. Inhibition of PDK partially restores oxidative phosphorylation, reducing cell proliferation and inflammatory cytokine secretion, suggesting glycolytic reprogramming supports the pathogenic phenotype of FLS.108,109 Glycolytic activation in FLS often accompanies lactate accumulation, decreased local pH, and activation of HIF-related transcriptional networks.110 In OA synovial tissue, elevated expression of pro-angiogenic molecules such as vascular endothelial growth factor A (VEGFA) correlates with inflammation, abnormal proliferation, and angiogenesis.111 Thus, metabolic alterations in FLS may contribute to creating a pro-angiogenic microenvironment, although the direct causal chain requires further confirmation. Overall, glycolytic reprogramming in FLS likely represents a key metabolic basis for sustained synovitis and pathological tissue remodeling. In contrast, lipid and amino acid metabolism in FLS remain less systematically studied in OA.83 Research on inflammatory synovial cells suggests lipid metabolism may support FLS proliferation and membrane synthesis, while amino acid metabolism, particularly glutaminolysis, provides supplemental carbon and nitrogen sources for their proliferative and secretory states.153 Chondrocytes Chondrocytes reside in a relatively hypoxic environment and are highly sensitive to metabolic changes.154,155 Normal chondrocytes already display significant glycolytic activity, but in OA this metabolic state becomes further imbalanced, closely linked to inflammation, aging, and matrix degradation.29,150 Recent evidence suggests simultaneous enhancement of glycolysis and inflammatory signaling in OA cartilage. Lactate-related metabolic changes may sustain inflammatory and catabolic programs through oxidative stress or lactylation mechanisms. However, certain glycolytic nodes such as PFKFB3 exhibit context-dependent roles across different OA models and disease stages.95,156 This indicates that glucose metabolic abnormalities not only affect energy homeostasis but may also contribute to degenerative processes via signal transduction and epigenetic regulation. Lipid metabolic abnormalities represent significant recent advances in OA chondrocyte metabolism research. Enhanced fatty acid oxidation in OA chondrocytes leads to acetyl-CoA accumulation, promoting a degenerative phenotype via dual metabolic-transcriptional/epigenetic mechanisms. Increased FAO reduces AMPK activity, impairs SOX9 phosphorylation, and promotes its ubiquitination and degradation. Concurrently, acetyl-CoA facilitates transcriptional activation of catabolic genes such as MMP13 and ADAMTS7, ultimately driving OA progression.96 Thus, lipid metabolism abnormalities in OA chondrocytes are not merely related to lipid droplet accumulation; they actively shape degenerative phenotypes via the FAO-acetyl-CoA regulatory axis.96 In terms of amino acid metabolism, glutamine metabolism is increasingly recognized for its role in OA chondrocyte inflammatory response and stress adaptation. It not only contributes significantly to TCA cycle anaplerosis but may also balance inflammation and cell survival through regulation of NF-κB signaling, autophagy, and stress responses. Furthermore, reduced glutathione synthesis and decreased GPX4 activity promote lipid peroxidation and susceptibility to ferroptosis, exacerbating chondrocyte damage.97–99 Overall, metabolic abnormalities in glucose, lipids, and amino acids act together in OA chondrocytes to induce mitochondrial dysfunction, oxidative stress, inflammation, and cell death. Gut-Derived Signals and Metabolic Reprogramming-Mediated Immune Imbalance During OA, local joint immune abnormalities do not merely result from local tissue damage but are continuously shaped by gut-derived inflammatory signals mediated by the gut-joint axis.14,15,19,30 Gut microbiota dysbiosis and impaired intestinal barrier function allow increased entry of LPS and other MAMPs into circulation, predisposing innate and adaptive immunity toward a pro-inflammatory state.30 Mechanistically, gut microbiota dysbiosis increases systemic exposure to LPS/MAMPs, alters SCFA, BA, and tryptophan derivative profiles, and exacerbates systemic low-grade inflammation. This increases local joint immune and structural cells’ susceptibility to metabolic reprogramming and chronic inflammation.14,15,19,157 In OA, gut-derived signals not only trigger transient immune activation but form a bidirectional feedback loop with local metabolic reprogramming. As discussed above, gut-derived inputs and local metabolic stress may reinforce each other, making joint inflammation more likely to transition from a reversible response to a chronic immunometabolic state.28 Thus, immune abnormalities in OA represent chronic immunometabolic imbalances driven by gut-derived signals and local metabolic changes. Innate Immune Imbalance In innate immunity, sustained recruitment and activation of myeloid cells constitute a cellular basis for persistent synovitis. Evidence suggests that the recruitment axis formed by C-C motif chemokine ligand 2 (CCL2) and C-C motif chemokine receptor 2 (CCR2) continuously attracts peripheral CCR2+ monocytes into synovial tissue, thereby replenishing local macrophage populations.105,158 Myeloid cells entering the synovium integrate PRR-related signals, particularly TLR-mediated MyD88-NF-κB/MAPK pathways and NLRP3 inflammasome activation, promoting continuous release of cytokines (IL-1β, TNF-α, IL-6) and chemokines, thereby stabilizing local inflammation.30,159,160 Continuous recruitment and activation more convincingly explain chronic synovitis maintenance compared to single inflammatory events. Synovial macrophages represent key effector cells driving persistent OA synovitis.161,162 Gut-derived signals increase macrophage pro-inflammatory sensitivity and hinder inflammation resolution by elevating local inflammatory load and oxidative stress.163,164 This sustained low-grade activation further transforms FLS from homeostatic support cells into highly proliferative, migratory, and secretory phenotypes. Activated FLS, in turn, secrete chemokines and inflammatory signals, perpetuating macrophage recruitment and activation. Thus, macrophage-FLS interactions constitute a crucial amplification loop in persistent OA synovitis. Adaptive Immune Imbalance Although traditionally considered degenerative, accumulating evidence highlights adaptive immunity’s role in OA development, notably the imbalance between Th17 and Tregs.112,113 Studies indicate enhanced Th17 responses in OA patient blood, synovium, and joint tissues. Conversely, decreased numbers, limited function, or insufficient stability of Tregs correlate with persistent inflammation and disease progression.114–117 This imbalance can be explained via metabolic reprogramming.118,119 Effector T cells generally rely on glycolysis for activation and cytokine secretion, whereas Tregs depend more on FAO and OXPHOS.120 Consequently, sustained inflammation and metabolic stress in OA favor glycolysis-dependent pro-inflammatory effector T cells. Oxidative metabolism-dependent Tregs become vulnerable to hypoxia, nutrient competition, and oxidative stress, resulting in insufficient restoration of immune tolerance.119 Therefore, OA-related T cell imbalance reflects differences in metabolic adaptability between T cell subsets rather than mere numerical changes. Under chronic inflammation, signals such as the IL-6–signal transducer and activator of transcription 3 (STAT3) pathway promote differentiation of naive CD4+ T cells toward Th17 responses, while reduced Treg numbers or function impair immune tolerance and inflammation resolution.113,114 Th17 factors enhance local inflammation and interact with synovial myeloid cells and FLS, increasing chemokine production and inflammation stability.157 Treg abnormalities manifest not only as decreased numbers but also limited suppressive capacity, phenotypic instability, or impaired function under inflammatory conditions.114 Insufficient immunoregulatory capacity thus holds greater pathological significance for OA than mere Treg reduction. Although CD8+ T cells and B cells also contribute to OA pathology, adaptive immunity research on gut-derived immunometabolic crosstalk currently emphasizes Th17/Treg metabolic adaptability imbalances. Extension from Immune Imbalance to Structural Damage The pathological significance of immune imbalance driven by gut-derived signals and metabolic reprogramming also lies in its capacity to progress from immune abnormalities to structural damage.165,166 Continuous activation of synovial macrophages and FLS results in local production of inflammatory mediators, proteases, and pro-catabolic factors. These factors inhibit anabolic metabolism and enhance catabolism in chondrocytes, thus exacerbating cartilage matrix degradation.165 Concurrently, DAMPs and degradation products released from damaged cartilage can reactivate synovial immune cells and FLS, creating a positive feedback loop in which synovitis promotes cartilage damage, while cartilage-derived DAMPs subsequently reinforce synovial activation, thereby sustaining OA chronicity and structural deterioration.167,168 Local Metabolic Microenvironment Changes and Pro-Inflammatory Feedback in OA The immune imbalance described above not only directly triggers inflammation but also reshapes the local microenvironment, inducing persistent metabolite profile shifts.80,102 These metabolic shifts also lead to persistent local changes, including lactate accumulation and acidification, increased TCA cycle intermediates (eg, succinate),80,169 elevated mitochondrial ROS, redox imbalance, and reduced availability of nutrients (glucose, amino acids).163,170 Notably, these changes are not merely passive metabolic outcomes; they act as diffusible metabolic regulators.167 Metabolic intermediates influence immune and structural cells in the synovium and cartilage via receptor signaling, transcriptional control, and epigenetic modifications.129,130 Such multi-metabolite positive feedback loops stabilize pro-inflammatory states and prevent natural inflammation resolution, constituting the pro-inflammatory feedback mechanism of the OA metabolic microenvironment. Pro-Inflammatory Effects of Lactate Accumulation and Acidic Microenvironment Enhanced glycolysis commonly leads to lactate accumulation and a reduced local pH in OA joints.171–173 In synovial and cartilage tissues, sustained inflammation, hypoxia, and metabolic shifts promote lactate production. Lactate and an acidic microenvironment further influence cellular inflammatory responsiveness, matrix metabolism, and angiogenesis.171,174 Studies indicate that lactate and acidity are not mere metabolic by-products but actively sustain synovitis and pathological remodeling via HIF-related transcriptional networks, intercellular communication, and inflammatory mediator production.172,173 Synergistic Amplification of ROS and Inflammasome Activation Mitochondrial dysfunction and ROS elevation are common manifestations of OA-related metabolic stress.175 Persistent inflammation and mechanical stress induce redox imbalance and ROS accumulation, exacerbating mitochondrial damage, inflammatory signaling, and cellular dysfunction. ROS not only directly damage chondrocytes and degrade the cartilage matrix but also activate inflammasomes, increasing release of pro-inflammatory cytokines (IL-1β, IL-18) and perpetuating inflammation.163,164,176 Hence, ROS elevation in OA represents a key mediator linking metabolic stress and chronic inflammation, not merely an injury consequence.167,177 Abnormal Lipid Load and Lipid-Mediated Inflammatory Regulation Besides affecting energy metabolism, lipid metabolic abnormalities also worsen the OA microenvironment through lipid peroxidation. Recent evidence indicates that enhanced fatty acid oxidation in chondrocytes, acetyl-CoA accumulation, and associated transcriptional/epigenetic changes increase catabolic gene expression, driving degeneration. Additionally, reduced glutathione synthesis and impaired GPX4 activity elevate lipid peroxidation and susceptibility to ferroptosis, aggravating chondrocyte stress injury and OA structural deterioration.97–99 In addition, prostaglandin E2 (PGE2), generated through the cyclooxygenase-2 (COX-2) pathway, exerts catabolic effects on OA cartilage by signaling through the prostaglandin E receptor 4 (EP4), suppressing proteoglycan synthesis, and upregulating MMPs and ADAMTSs; PGE2 also acts on subchondral bone osteoclasts to drive structural progression.178–180 Tissue-Level Amplification Through Synovium-IPFP-Cartilage/Subchondral Bone Crosstalk Immunometabolic crosstalk not only occurs at single-cell and molecular levels but also amplifies spatially among the synovium, IPFP, cartilage, and subchondral bone. Studies suggest the synovium and IPFP function in close immune-metabolic coordination in OA, jointly accumulating myeloid cells and maintaining a microenvironment characterized by sustained inflammation and metabolic abnormalities via chemokines, paracrine mediators, and angiogenesis.15,121 Single-cell analyses of rheumatoid arthritis (RA) synovium, used here only as a comparator, further illustrate how disease-associated fibroblast and myeloid subsets can amplify joint inflammation, providing a conceptual framework that may inform OA studies.122,123 However, these RA-derived cellular interaction patterns should be interpreted cautiously and require direct validation in OA synovial tissues. The IPFP acts as a source of bioactive mediators within joints. Secreted lipid mediators, adipokines, and cytokines (eg, IL-6) accumulate locally and transmit metabolic injury signals to cartilage and subchondral bone, exacerbating chondrocyte oxidative stress, lipid peroxidation, and ferroptosis-associated damage, thus accelerating OA degeneration.121,124–126 Additionally, IPFP-derived leptin and other adipokines can disrupt the receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) balance, enhance osteoclast activity, and promote abnormal subchondral bone remodeling in systemic metabolic disorders.126 Changes in subchondral bone microstructure and mechanical properties alter joint load distribution, indirectly intensifying cartilage damage via abnormal stress transmission. This creates a pathological cascade in which adipokine abnormalities promote subchondral bone remodeling, disrupt mechanical stress distribution, and ultimately accelerate cartilage degeneration.155,166 Thus, the synovium, IPFP, cartilage, and subchondral bone form an inter-tissue amplification network through paracrine signaling, substrate exchange, and cell migration, spatially propagating and temporally prolonging local inflammatory and metabolic stress.127,165 Influence of Systemic Immunometabolic Status on Chronic Inflammation and Structural Degeneration Chronic inflammation and structural degeneration in OA are not limited to the local joint but are shaped by long-term systemic immunometabolic status. Metabolic organs (gut, adipose tissue, liver) regulate circulating metabolites, inflammatory mediators, and substrate supply, thereby setting immune response thresholds. Concurrently, local metabolic changes (lactate/acidosis, succinate accumulation, oxidative stress) restrict inflammation resolution and restoration of homeostasis, collectively sustaining OA chronicity.15,127,153,157,163,167,169,171 Therapeutic Strategies Targeting the Gut-Joint Axis and Clinical Translation Recent interventions go beyond symptom relief, aiming to regulate the gut-joint inflammatory cascade from gut-derived inputs through systemic immunometabolic imbalances to local joint effects. Current trends in treating inflammatory diseases favor precise targeted strategies rather than broad-spectrum anti-inflammatory approaches. Such precise interventions aim to interrupt pathological inflammatory cascades while preserving physiological immune function, minimizing systemic side effects, and achieving sustainable therapeutic outcomes. Gut Microbiota Remodeling Dietary and Metabolite Regulation Diet strongly influences microbiota composition and metabolite production. High-fiber diets promote butyrate-producing bacteria and increase SCFA levels. A study by Schott et al91 suggested that prebiotic fiber interventions partially corrected gut dysbiosis under a high-fat diet, accompanied by improved intestinal mucosal barrier markers and reduced synovial inflammation. This “diet-metabolite-immunity” axis provides a feasible entry point for modulating host inflammatory tolerance.31,32,133 Probiotics/Synbiotics Probiotics, such as Lactobacillus strains, can improve barrier function and are linked to reduced pain and better joint function. Some studies have also suggested that such interventions alter choline and amino acid metabolic profiles, with trends toward reduced unfavorable changes in cartilage catabolism-related indicators.49,63,181 However, substantial heterogeneity exists among studies in strains, doses, treatment duration, and baseline characteristics, which limits comparability.31,32,133 Intestinal Mucosal Barrier Repair and Control of Gut-Derived Input If the gut-joint axis is considered an “inflammatory input-amplification” model, the intestinal mucosal barrier functions as the key gateway determining input intensity. Enhancing tight junction proteins via diet or small molecules decreases LPS translocation, supporting systemic and joint homeostasis. A randomized double-blind trial by Karim et al49 reported that probiotic supplementation improved mucosal barrier function and was associated with reduced OA severity. Importantly, barrier improvement does not indicate structural repair but reflects reduced inflammatory input, thereby providing systemic conditions for subsequent immunometabolic and joint microenvironment recovery. Furthermore, under dysbiosis and barrier vulnerability, mechanical joint injury is more likely to trigger amplified inflammation. Therefore, targeting barrier homeostasis may reduce post-injury inflammatory amplification and delay disease progression.31,32,49 Immunometabolic Node Regulation and Signal Blockade When inflammatory signals circulate, treatments aim to inhibit amplification pathways and normalize immune cell metabolism. Clinically, a randomized controlled trial by Pan et al134 demonstrated that metformin improved pain in overweight or obese patients with knee OA, consistent with broader preclinical and clinical evidence supporting metformin (an AMPK activator) as a candidate disease-modifying agent for metabolic-phenotype OA.135 Studies and reviews on GLP-1 receptor agonists indicate additional translational potential in OA populations with metabolic disorders.133,136,182,183 Mechanistically, targeting PRR-related pathways and the NLRP3 inflammasome (eg, TLR4 inhibitor TAK-242, NLRP3 inhibitor MCC950) can reduce pro-inflammatory outputs such as IL-1β and are associated with attenuation of cartilage and subchondral bone degeneration.24,184,185 Targeting the Local Joint Microenvironment: Synovitis, Cartilage Catabolism, and Subchondral Bone Remodeling Although the gut-joint axis emphasizes upstream inflammatory inputs, the local joint microenvironment ultimately determines how these signals translate into clinical symptoms and structural damage. Besides core non-pharmacological interventions such as exercise.186 Drugs targeting macrophage activation and matrix degradation are in development, but current therapies imperfectly control symptoms or structure. Bisphosphonates (eg, zoledronic acid) may reduce short-term pain and bone marrow lesions (BMLs), but show no long-term cartilage or BML benefit.187–189 A conceptual blueprint for these biomarker-guided stratified intervention strategies along the gut–joint axis is presented in Figure 3. Figure 3Biomarker-guided stratified intervention strategies along the gut-joint axis in OA. This schematic illustrates a stratified intervention framework for OA based on gut-joint axis-related phenotypes and biomarkers. Patients are categorized into metabolic-inflammatory, biomechanical, or mixed phenotypes. Biomarker-guided approaches then identify microbiota/metabolite signatures, barrier dysfunction markers, and joint inflammatory features. Intervention modules include microbiota modulation, barrier repair, immunometabolic checkpoint regulation, and joint tissue protection. Goals include reducing systemic and local inflammatory burdens, improving joint microenvironment homeostasis, relieving symptoms, and slowing structural progression. Key translational barriers include phenotype heterogeneity, biomarker inconsistency, pain-structure discordance, and uncertainty regarding long-term efficacy.The schematic outlines a biomarker-guided stratified intervention framework for osteoarthritis along the gut-joint axis. It is organized as a top-to-bottom flowchart progressing from patient stratification to biomarker-guided identification, intervention modules, and clinical translation. Patients are stratified into metabolic-inflammatory OA, biomechanical OA, and mixed phenotype. Biomarker-guided identification includes microbiota/metabolite signatures, barrier dysfunction markers, and inflammatory joint phenotype. These guide intervention modules comprising microbiota modulation, barrier repair, immunometabolic checkpoint modulation, and joint tissue protection, with arrows indicating restoration of microbial ecology, reinforcement of the intestinal barrier, and interruption of inflammatory amplification. Clinical translation highlights expected benefits, including reduced metaflammation and synovitis, improved pain and function, and slower structural progression, alongside translational bottlenecks such as phenotype heterogeneity, biomarker inconsistency, pain-structure discordance, long-term uncertainty, and the need for phenotype-stratified trials.A schematic of biomarker-guided interventions for osteoarthritis along the gut-joint axis. Biomarker-guided stratified intervention strategies along the gut-joint axis in OA. This schematic illustrates a stratified intervention framework for OA based on gut-joint axis-related phenotypes and biomarkers. Patients are categorized into metabolic-inflammatory, biomechanical, or mixed phenotypes. Biomarker-guided approaches then identify microbiota/metabolite signatures, barrier dysfunction markers, and joint inflammatory features. Intervention modules include microbiota modulation, barrier repair, immunometabolic checkpoint regulation, and joint tissue protection. Goals include reducing systemic and local inflammatory burdens, improving joint microenvironment homeostasis, relieving symptoms, and slowing structural progression. Key translational barriers include phenotype heterogeneity, biomarker inconsistency, pain-structure discordance, and uncertainty regarding long-term efficacy. Natural Products and Phytochemicals The potential value of natural products and phytochemicals in the gut–joint axis lies in their potential to modulate multiple pathogenic nodes, including microbial functional outputs, mucosal barrier homeostasis, inflammatory signal amplification, and local joint metabolic stress.137–143 Polysaccharides Polysaccharides generally exhibit poor absorption in the upper digestive tract and primarily serve as substrates for gut microbial fermentation. Thus, their effects resemble prebiotic interventions. Such components mainly influence the upstream aspects of the gut-joint axis by modulating microbial composition, promoting SCFA production, enhancing epithelial energy supply, and supporting tight junction integrity, thereby reducing gut-derived inflammatory inputs.137,142 A recent study showed that Lycium barbarum polysaccharide reduced cartilage damage in a destabilization of the medial meniscus (DMM)-induced mouse OA model. This effect was accompanied by inhibition of chondrocyte ferroptosis and an increased intestinal Lactobacillus/Alistipes ratio, indicating that Lycium barbarum polysaccharide may alleviate OA progression by modulating gut microbiota and inhibiting chondrocyte ferroptosis.137,142,144 Alkaloids Berberine is a representative alkaloid. On the one hand, Berberine enhances metabolic profiles and decreases systemic low-grade inflammation in metabolic disorders. On the other hand, in OA-related studies, oral berberine reduced structural damage and alleviated pain in post-traumatic OA mice; these beneficial effects were significantly reduced in AMPKα1-deficient animals. In human primary knee OA chondrocytes, berberine induced liver kinase B1-dependent AMPKα (Thr172) phosphorylation, accompanied by increased expression of sirtuin 1 and sirtuin 3. Thus, the protective effects of berberine may relate to activation of the AMPK-mediated energy-sensing pathway.137,142,145 Polyphenols/Flavonoids Polyphenols and flavonoids modulate inflammation, oxidative stress, and cellular metabolism. Their high gastrointestinal exposure also affects gut microbes, metabolite levels, and barrier integrity. From a gut-joint axis perspective, these compounds possess dual potential for upstream gut modulation and downstream joint protection.137,140–142,146–148 Curcumin is a representative compound with robust clinical evidence. A network meta-analysis of randomized controlled trials indicated that curcumin improved knee OA pain and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, with fewer adverse events compared to non-steroidal anti-inflammatory drugs (NSAIDs). Thus, curcumin represents a feasible option for symptomatic management.140,141 A recent systematic review and meta-analysis demonstrated that resveratrol reduced inflammatory markers, including IL-1β, TNF-α, IL-6, and nitric oxide, decreased chondrocyte apoptosis, and improved joint structure-related outcomes in animal OA models. These findings suggest resveratrol impacts OA progression through anti-inflammatory, antioxidant, and cartilage-protective mechanisms.146 A study in OA rats showed that quercetin treatment altered gut microbiota composition and metabolomic profiles, suggesting dual effects involving local anti-inflammatory actions and modulation of gut microbiota and host metabolism. Compared with curcumin and resveratrol, quercetin exemplifies natural products’ dual characteristics in gut regulation and joint protection.147,148 Discussion Current studies suggest that the gut-joint axis offers a useful framework to explain how systemic low-grade inflammation and metabolic disturbances relate to local joint degeneration in OA.14–16 Its significance lies not in replacing classical theories (eg, mechanical load, aging, injury), but in offering an additional explanation for why OA associated with obesity, insulin resistance, and metaflammation may show sustained synovial inflammation, cartilage matrix catabolism, and structural progression.5,11,14,15 Compared with previous reviews that primarily summarized microbiota alterations, gut–joint associations, or individual microbiota-targeted interventions, the present review provides a more integrated mechanistic synthesis. Its novelty lies in placing immunometabolic reprogramming at the center of the gut–joint axis, linking dysbiosis, barrier dysfunction, microbial metabolites, MAMP exposure, and PRR signaling to persistent changes in synovial macrophages, FLS, and chondrocytes. This framework also extends beyond mechanism by proposing a biomarker-guided and phenotype-oriented intervention blueprint for metabolic-inflammatory OA. The strength of evidence in this field is not uniform. Population-based studies mainly support associations of microbiota, metabolites, and barrier abnormalities with OA.16,22,33,40,50,54,77,87,89 Studies using germ-free animals, fecal microbiota transplantation, and metabolite-receptor pathways provide stronger causal evidence.77,89–92 This indicates that the gut-joint axis is likely an amplifying factor rather than an independent initiating factor in OA progression. It likely functions by reducing the inflammatory threshold of the joint to mechanical stress and micro-injury via gut-derived inflammatory signals and metabolic disturbances.14,15 The evidence-grading framework also highlights that several mechanistic links remain incompletely validated in OA. In particular, some immune-cell circuits, trained immunity-like changes, epigenetic-locking mechanisms, and oral–gut–immune pathways are partly extrapolated from rheumatoid arthritis, other inflammatory arthritides, or broader immunometabolic literature. These mechanisms should therefore be regarded as hypothesis-generating and require direct validation in OA models, OA synovial tissues, or patient-derived joint cells. Mechanistically, gut dysbiosis and impaired intestinal barrier function reduce protective metabolites (SCFAs, BAs, tryptophan derivatives) and increase exposure to MAMPs (eg, LPS). These changes activate pathways such as TLR4-NF-κB/MAPK and the NLRP3 inflammasome, and induce metabolic reprogramming in synovial macrophages, FLS, and chondrocytes. Ultimately, these processes form a positive feedback loop amplifying inflammation and metabolic stress. Therefore, immunometabolic crosstalk in OA is not purely local but results from interactions among gut-derived input, systemic metabolic inflammation, and the joint microenvironment.14,15,28 Nevertheless, current evidence is insufficient to directly adopt the gut-joint axis as a mature stratification tool for OA. OA itself is highly heterogeneous, and factors (eg, diet, medications, obesity, metabolic comorbidities) influence microbiota- and barrier-related indicators. Meanwhile, the specificity and stability of surrogate markers (eg, LPS, LBP, zonulin) remain limited.19,22,51,52,54 Overall, the gut-joint axis is more suited to explain progression in specific OA subtypes, particularly those linked to metabolic disorders, rather than providing a universal diagnostic or treatment guideline. Its clinical value lies in guiding stratified intervention strategies for OA linked to obesity or metabolic disorders, shifting OA research from a purely local degenerative perspective to one emphasizing system–local coupled imbalances. Conclusion The gut–joint axis should be viewed primarily as an amplifier of inflammatory and metabolic susceptibility in OA rather than as an independent initiating factor. By increasing gut-derived inflammatory inputs and lowering the inflammatory threshold of joint tissues, gut dysbiosis and impaired intestinal barrier function may help explain why metabolic-inflammatory OA phenotypes are more prone to persistent local inflammation and structural progression. Clinically, this framework may support the biomarker-guided identification of patients who could benefit from interventions targeting microbiota homeostasis, intestinal barrier integrity, and immunometabolic pathways alongside standard biomechanical and symptom-directed management. Future Directions Future research should prioritize longitudinal, phenotype-stratified cohorts integrating metagenomics, metabolomics, intestinal barrier biomarkers, and joint-tissue profiling to validate causal pathways and develop robust composite biomarkers. Biomarker-guided clinical trials should subsequently evaluate precision microbiota modulation, barrier-repair strategies, and immunometabolic interventions, with long-term assessment of pain, function, and structural disease progression.31,32,54,133